Treatment of acute promyelocytic leukemia with PETHEMA LPA 99 protocol: a Tunisian single center experience

References

• Fenaw P, Chastang C, Chevret S et al. A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 14: 1192–1200.
   Google Scholar
• Sanz MA, Martin G, Gonzalez M et al. Risk adapted treatment of acute promyelocytic leukemia with all trans retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103: 1237–1243.
   PubMed Web of Science ®Google Scholar
• Mandelli F, Diverio D, Avvisati G et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014–1021.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Grimwade D, Tallman MS et al. Management of acutepromyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113: 1875–1891.
   PubMed Web of Science ®Google Scholar
• Lo Coco F, Cimino G, Breccia M et al. Gemtuzumab ozogamicin(Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004; 104: 1995–1999.
   PubMed Web of Science ®Google Scholar
• Au WY, Chim CS, Lie AK et al. Treatment of relapsed acute promyelocytic leukemia by arsenic-based strategies without hema-topoietic stem cell transplantation in Hong Kong: a seven-year experience. Blood 2004; 104: Abstract 395.
   Web of Science ®Google Scholar
• Au WY, Kumana CR, Kou M et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 2003; 102: 407–408.
   PubMed Web of Science ®Google Scholar
• Jeddi R, Hdiji S, Kacem K et al. [Therapeutic results with APL 93protocol in acute promyelocytic leukemia (34 cases)]. Tunis Med 2006; 84: 717–720.
   PubMedGoogle Scholar
• Sanz MA, Lo Coco F, Martin G et al. Definition of relapse riskand role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247–1253.
   PubMed Web of Science ®Google Scholar
• Ades L, Chevret S, Raffoux E et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a rando-mized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006; 24: 5703–5710.
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Haferlach C, Saussele S et al. High dose ara-C in thetreatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia 2009; 23: 2248–2258.
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Saussele S, Haferlach T et al. Treatment of newly diagnosed acute promyelocytic leukemia: the impact of high dose ara-C. Blood 2003; 102: Abstract 448.
   Web of Science ®Google Scholar
• Ades L, Sanz MA, Chevret S et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French—Belgian—Swiss and PETHEMA results. Blood 2008; 111: 1078–1084.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Grimwade D, Solomon E et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 1999; 93: 4131–4143.
   PubMed Web of Science ®Google Scholar
• de la Serna J, Montesinos P, Vellenga E et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 11: 3395–3402.
   Google Scholar
• Tallman MS, Andersen JW, Schiffer CA et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000; 95: 90–95.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Berqua JM, Vellenga E et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009; 113: 775–783.
   PubMed Web of Science ®Google Scholar
• Jeddi R, Ghédira H, Mnif S, Gouider E, Fenaux P, Meddeb B. High body mass index is an independent predictor of differentia-tion syndrome in patients with acute promyelocytic leukemia. Leuk Res 2010; 34: 545–547.
   PubMed Web of Science ®Google Scholar
• de Botton S, Dombret H, Sanz M et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 1998; 92: 2712–2727.
   PubMed Web of Science ®Google Scholar
• Estey E, Thall P, Kantarjian H et al. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia 1997; 11: 1661–1664.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Mikhail A, Estov Z et al. Expression and function ofleptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptic activities. Blood 1999; 93: 1668–1676.
   PubMed Web of Science ®Google Scholar
• Tabe Y, Konopleva M, Munsell MF et al. PML-RAR-a is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood 2004; 103: 1815–1822.
   PubMed Web of Science ®Google Scholar
• Lazo G, Kantarjian H, Estey E et al. Use of arsenic trioxide (As203) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer 2003; 97: 2218–2224.
   PubMed Web of Science ®Google Scholar
• Niu C, Yan H, Yu T et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315–3324.
   PubMed Web of Science ®Google Scholar
• Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852–3860.
   PubMed Web of Science ®Google Scholar
• Meloni G, Diverio D, Vignetti M et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 1997; 90: 1321–1325.
   PubMed Web of Science ®Google Scholar
• de Botton S, Fawaz A, Chevret S et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelo-cytic leukemia initially treated with all- trans-retinoic acid: a retrospective analysis of the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2005; 23: 120–126.
   PubMed Web of Science ®Google Scholar
• Linker CA. Autologous stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant 2003; 31: 731–738.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Romano A, Mengarelli A et al. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. Leukemia 2003; 17: 1930–1933.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Labopin M, Gorin NC et al Acute Leukemia Working Party (ALWP) of European Cooperative Group for Blood and Marrow Transplantation (EBMT). Hematopoietic stem cell transplan-tation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2007; 39: 461–469.
   PubMed Web of Science ®Google Scholar
• Latagliata R, Petti MC, Fanu S, Mancini M, Aloe Spiritti MA. Therapy related myelodysplastic syndrome—acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002; 99: 822–824.
   PubMed Web of Science ®Google Scholar
• Lobe I, Rigal-Huguet F, Vekhoff A et al. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia 2003; 17: 1600–1604.
   PubMed Web of Science ®Google Scholar
• Jeddi R, Gouider E, Ben Neji H et al. Secondary chronic myelomonocytic leukemia with monosomy 7 after successful treatment of acute promyelocytic leukemia. Pathol Biol (Paris) 2009; 56: 162–163.
   Web of Science ®Google Scholar